5. EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome

6. EXAMINE: CV End Points

7. SAVOR-TIMI 53 Study: Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications?

8. SAVOR-TIMI 53: CV End Points

9. Safety End Points

10. Clinical Implications

11. CV Events With Rosiglitazone

12. Global Cost of Diabetes

13. Insights From SAVOR-TIMI 53

14. DPP-4 Inhibitors

15. Hypoglycemia: Impact on Quality of Life

16. Take-Home Messages

17. Abbreviations

18. Abbreviations (cont)

19. References

20. References (cont)

21. References (cont)